Genetic knockdown, knockout, or pharmacological inhibition of PUS7 reduces proliferation across various cancer cell types, such as pancreatic cancer [61], clear cell renal cell carcinoma [65], neuroblastoma [18], non-small cell lung cancer [70], colorectal cancer [62,64], and glioblastoma stem-like cells derived from diverse GBM subtypes [53], and leads to decreased tumor cell viability, increased apoptosis, and impaired tumor growth in vivo (Table 3, Figure 1). Here, PUS7 is linked to neoplasm.